TREAT YOUR ELIGIBLE PATIENTS WITH FLEXIBILITY

Patients could receive as few as 10 injections over 3 years as per the dosing schedules in the PULSAR and PHOTON trial protocols.

The frequency of monitoring visits should be based on the patient’s status and at the physician’s discretion.

Dosing diagram for illustrative purpose only.

*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to 6 months (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable.

^†Stable patients switching to EYLEA 8 mg do not require loading doses and can maintain or extend previous treatment intervals after the first injection of EYLEA. Consult the SmPC for full posology.

^‡For patients who have previously been treated with EYLEA 2 mg or other anti-VEGF medicinal products and are switching to EYLEA 8 mg, the treatment regimen can differ from that used for treatment-naïve patients. Treatment intervals should be determined based on visual and/or anatomic outcomes: In patients with stable visual and anatomic outcomes, previous treatment intervals can be maintained or extended after the first injection of EYLEA 114.3 mg/mL, such as with a T&E dosing regimen; in patients with suboptimal visual and/or anatomic outcomes, treatment with EYLEA 8 mg may begin with 1 injection per month for up to 3 consecutive doses followed by adjustment of injection intervals, such as with a T&E dosing regimen.

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).

Abbreviations

DMO, diabetic macular oedema. nAMD, neovascular (wet) age-related macular degeneration. Q16, every 16 weeks. Q24, every 24 weeks. SmPC, Summary of Product Characteristics. T&E, treat and extend. VEGF, vascular endothelial growth factor.